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https://doi.org/10.1016/j.celrep.2021.109292SUMMARYWe report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike DH69/V70 in multiple inde-
pendent lineages, often occurring after acquisition of receptor binding motif replacements such as N439K
and Y453F, known to increase binding affinity to the ACE2 receptor and confer antibody escape. In vitro,
we show that, although DH69/V70 itself is not an antibody evasion mechanism, it increases infectivity
associated with enhanced incorporation of cleaved spike into virions. DH69/V70 is able to partially rescue
infectivity of spike proteins that have acquired N439K and Y453F escapemutations by increased spike incor-
poration. In addition, replacement of the H69 and V70 residues in the Alpha variant B.1.1.7 spike (where
DH69/V70 occurs naturally) impairs spike incorporation and entry efficiency of the B.1.1.7 spike pseudotyped
virus. Alpha variant B.1.1.7 spike mediates faster kinetics of cell-cell fusion than wild-type Wuhan-1 D614G,
dependent on DH69/V70. Therefore, as DH69/V70 compensates for immune escape mutations that impair
infectivity, continued surveillance for deletions with functional effects is warranted.INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
spike surface glycoprotein engagement of human angiotensin-
converting enzyme (hACE2) is essential for virus entry and infec-
tion (Zhou et al., 2020), and the receptor is found in the respira-
tory and gastrointestinal tracts (Sungnak et al., 2020). Despite
this critical interaction and the imposed constraints, it appears
that the receptor binding domain (RBD) is relatively tolerant to
mutations (Starr et al., 2020b; Thomson et al., 2020), raising
the real possibility of virus escape from past infection or vac-This is an open access article undcine-induced immunity (Cele et al., 2021; Collier et al., 2021;
Gupta, 2021; Madhi et al., 2021) and monoclonal antibody treat-
ments (Starr et al., 2021). Spike mutants exhibiting reduced sus-
ceptibility to neutralizing antibodies have been identified in
in vitro screens (Greaney et al., 2021a, 2021b; Starr et al.,
2020a), and some of these mutations have been found in clinical
isolates (Choi et al., 2020).
Studying chronic SARS-CoV-2 infection can give insights into
virus evolution that would require many chains of acute transmis-
sion to generate. This is because themajority of infections arise as
a result of early transmission during pre- or asymptomatic phasesCell Reports 35, 109292, June 29, 2021 ª 2021 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Global snapshot of SARS-CoV-2 lineages associated with DH69/V70 and RBM mutations
(A) Maximum-likelihood phylogeny of global SARS-CoV-2 whole-genome sequences, highlighting those with specific mutations in spike: DH69/V70, N439K,
Y453F, and N501Y. The tree is subsampled, and tips are colored by geographic region (see key). Grey bars on the right show the presence or absence of the
DH69/V70 and amino acid variants N439K, Y453F, and N501Y. Pangolin lineages are shown.
(legend continued on next page)






OPEN ACCESSprior to peak adaptive responses, and virus adaptation is not
observed because the virus is usually cleared by the immune
response (He et al., 2020; Mlcochova et al., 2020). We recently
documented de novo emergence of antibody evasion mutations
mediated by spike gene mutations in an individual treated with
convalescent plasma (CP) (Kempetal., 2021). In addition, achron-
ically infected immune-suppressed individual has been reported
recently in Russia with emergence of Y453F along with DH69/
V70 (Bazykin et al., 2021).Deletions inother parts of theN-terminal
domain (NTD) have been reported to arise in chronic infection
(Choi et al., 2020) and reduce sensitivity to NTD-specific neutral-
izing antibodies (McCallum et al., 2021; McCarthy et al., 2021).
Here we analyze global SARS-CoV-2 data and find that
DH69/V70 occurs independently, often emerging after a sig-
nificant RBD amino acid replacement, such as Y453F and
N439K, which are known to facilitate neutralizing antibody
escape or alter ACE2 binding while incurring an infectivity
defect, according to some reports (Motozono et al., 2021;
Thomson et al., 2021). Although structural modeling indicates
that H69/V70 is in an exposed loop that contracts after dele-
tion, potentially altering an antigenic site, we report that the
DH69/V70 does not confer significantly reduced susceptibility
to convalescent sera or monoclonal antibodies (mAbs). Func-
tionally, we find that DH69/V70 does increase spike infectivity
and compensates for an infectivity defect resulting from the
RBD replacements N439K and Y453F. The infectivity increase
is driven by higher levels of spike incorporation into virions.
We demonstrate that the deletion is required for optimal infec-
tivity of the 501Y.V1 (B.1.1.7) spike protein. We show that,
although B.1.1.7 and the wild-type (WT) spike pseudotyped
virus (PV) have similar infectivity on a range of target cell
types, the B.1.1.7 spike protein alone induces more rapid
cell-cell fusion and formation of multinucleated cells. Repair
of the two amino acids not only leads to reduced
B.1.1.7 spike incorporation into virions and impaired infectivity
but also reduces cell-cell fusion kinetics back to WT levels.
RESULTS
Multiple occurrences and transmission of spike DH69/
V70 with and without spike mutations
The deletion H69/V70 is present in over 600,000 SARS-CoV-2
genome sequences worldwide and has seen global expansion,
particularly across much of Europe, Africa, and Asia (Figure 1).
DH69/V70 is observed in multiple global lineages (Figure 1A).
Although variants with deletions in this region of spike are
observed in GISAID (Shu and McCauley, 2017), the earliest un-
ambiguous sequences that included the DH69/V70 were de-
tected on a D614 background in January 2020 (United States
and Thailand). The earliest DH69/V70 detected on a D614G
background occurred in Sweden in April 2020. Prevalence of
DH69/V70 has increased since August 2020 (Figure 1B). Further
analysis of sequences revealed, first, that single deletion of H69
or V70 was uncommon and, second, that some lineages of(B and C) Cumulative occurrences of SARS-CoV-2 sequences with DH69/V70 by
N501Y. Indicated frequencies are by month, and all data were collected from th
reporting country and sampling date.DH69/V70 alone were present as well as DH69/V70 in the
context of other mutations in spike, specifically those in the re-
ceptor binding motif (RBM; Figure 1).
DH69/V70 is not a neutralizing antibody escape
mechanism
We hypothesized that DH69/V70 might confer reduced suscep-
tibility to neutralizing antibodies. We first examined the protein
structural context of DH69/V70 for clues regarding alterations
in epitopes (Figures 2A and 2B). In the absence of experimentally
derived structural data for DH69/V70, the protein structure of the
NTD possessing the double deletion was modeled in silico. The
DH69/V70 was predicted to alter the conformation of a protrud-
ing loop comprising residues 69–76, pulling it in toward the NTD
(Figure 2B). In the post-deletion structural model, the positions of
the alpha carbons of residues on either side of the deleted resi-
dues, Ile68 and Ser71, were each predicted to occupy positions
2.9 Å from the positions of His69 and Val70 in the pre-deletion
structure. Concurrently, the positions of Ser71, Gly72, Thr73,
Asn74, and Gly75 are predicted to have changed by 6.5 Å,
6.7 Å, 6.0 Å, 6.2 Å, and 8 Å, respectively, with the overall effect
of these residues moving inward, resulting in a less dramatically
protruding loop.
This predicted change in the surface of spike could be consis-
tent with antibody evasion. To test this, we explored whether
DH69/V70 conferred reduced susceptibility to neutralizing anti-
bodies in sera from 15 recovered individuals (Figures 2C and
2D). We performed serial dilutions of sera before mixing with len-
tiviral particles pseudotypedwith spike proteins with andwithout
DH69/V70 (with virus input normalized for infectivity). We plotted
infection of target cells as a function of serumdilution (Figure 2D).
All but two sera demonstrated clear titratable neutralization of
WT andDH69/V70 virus. There was no overall change in suscep-
tibility to serum neutralization for DH69/V70 relative to the WT
(Figure 2C), but there was a proportion of individuals with slightly
increased neutralization sensitivity of DH69/V70 (Figures 2C and
2D). To further explore the role of DH69/V70 in inducing immune
escape, we tested the binding of 12 NTD mAbs to the WT and
DH69/V70 NTD by biolayer interferometry (Figures 2E–2G). All
NTD mAbs showed less than a 2-fold decrease in binding to
DH69/V70 compared with the WT. These data suggest that
DH69/V70 does not represent an important antibody escape
mechanism.
DH69/V70 spike enhances infectivity associated with
increased cleaved S incorporation
We hypothesized that the deletion might, alternatively, enhance
virus infectivity. In the absence of virus isolates, we used a lenti-
viral PV approach to test the effect of DH69/V70 on virus spike
protein-mediated entry. D614G bearing Wuhan-1 spike-ex-
pressing DNA plasmid (WT) was co-transfected in HEK293T pro-
ducer cells along with plasmids encoding a lentiviral capsid and
genome for luciferase. Infectivity was adjusted for input reverse-
transcriptase activity; we observed a 2-fold increase in PVmonth for (B) DH69/V70 with or without N439K/Y453F and (C) DH69/V70 with
e GISAID database (http://gisaid.org, accessed May 21, 2021) and sorted by
Cell Reports 35, 109292, June 29, 2021 3
Figure 2. Spike DH69/V70 does not reduce sensitivity to neutralizing antibodies
(A) Surface representation of the spike homotrimer in the open conformation (PDB: 7C2L), with eachmonomer shown in different shades of gray. On themonomer
shown positioned to the right, the exposed loop consisting of residues 69–77 is shown in cyan and the neutralizing antibody (4A8)-binding NTD epitope in
magenta.
(B) Prediction of conformational change in the spike NTD because of deletion of residues His69 and Val70. The pre-deletion structure is shown in cyan, except for
residues 69 and 70, which are shown in red. The predicted post-deletion structure is shown in green. Residues 66–77 of the pre-deletion structure are shown in
stick representation and colored by atom (nitrogen in blue, oxygen in coral). Yellow lines connect aligned residues 66–77 of the pre- and post-deletion structures,
and the distance of 6 Å between aligned alpha carbons of Thr73 in the pre- and post-deletion conformation is labeled.
(C) Neutralization of spike DH69/V70 PV and WT (D614G background) by convalescent sera from 15 donors. GMT (geometric mean titer) with SD presented is
representative of two independent experiments, each with two technical repeats. Wilcoxon matched-pairs signed-rank test; ns, not significant.
(D) Ten example neutralization curves. Indicated is serum log10 inverse dilution against percent neutralization. Data points represent means of technical repli-
cates, and error bars represent SD. Curves are representative of two independent experiments.
(legend continued on next page)






OPEN ACCESSinfectivity of DH69/V70 compared with the WT in HeLa cervical
epithelial cells stably expressing human ACE2 (Figures 3A and
3B). We observed similar fold increases with DH69/V70 in a
range of other target cells in the context of overexpression of
ACE2/TMPRSS2 (HEK293T cells transiently transfected with
ACE2, or ACE2 and TMPRSS2 and A549 lung cells stably ex-
pressing ACE2 and TMPRSS2; Rihn et al., 2021) or endogenous
levels of receptors in Calu-3 lung adenocarcinoma cells
(Figure 3A).
Western blotting for S2 spike indicated a higher amount of
cleaved spike in DH69/V70 bearing virions and in the HEK293T
producer cell lysates. We also noted a corresponding reduction
in uncleaved full-length (FL) spike (Figure 3C). Densitometric
analysis of spike and p24 from western blots in multiple experi-
ments showed almost a 2-fold increase in the spike:p24 ratio
as well as an increased ratio in S2:FL cleavage for DH69/V70,
indicating that increased spike incorporation into virions might
explain the increase in infectivity (Figures 3D and 3E). To verify
that this increase in S from producer cells was not specific to
HEK293T cells, we also transfected the human lung epithelial
cell line H1299 (Zhang et al., 2020) with spike and lentiviral pack-
aging plasmids. We again observed that viruses from these cells
had 2-fold increased infectivity in target cells (Figure 3F). In addi-
tion, the increased total and cleaved S levels were recapitulated
in the cell lysates and purified virions from these lung cells (Fig-
ures 3G and 3H). Therefore, we conclude that the increased S
cleavage and its incorporation observed in producer cells and
pseudotyped virions is a generalized phenomenon for DH69/
V70S. To explorewhether D614Gwas required for this enhanced
spike cleavage and infectivity, we generated PVs bearing D614
spike with and without DH69/V70, followed by infection of
HEK293T cells. We observed a similar 2-fold enhancement of
infection and a proportional increase in spike incorporation as
we did for D614G spike PVs (Figures S1A and S1B). Finally, to
exclude the possibility that increased incorporation of Swas spe-
cific for pseudotyped lentiviral particles, we generated coronavi-
rus-like particles by co-transfection of WT or DH69/V70 S with
SARS-CoV-2 membrane (M), envelope (E), and nucleocapsid
(N) proteins, as described previously (Swann et al., 2020; Yurko-
vetskiy et al., 2020). Compared with levels of N, levels of cleaved
S in coronavirus-like particles were again enhanced in the pres-
ence of the DH69/V70 (Figures S1C and S1D).
Enhanced infectivity of DH69/V70 spike is not
correlated with cleavage or entry route
SARS-CoV-2 entry into target cells is thought to take place by
two distinct routes following binding to ACE2 (Figure 4A). The
first is an endosomal route where cathepsin is able to cleave
spike with pH-dependent fusion in the endosome. The second
route involves fusion at the plasma membrane with cleavage(E–G) Kinetics of binding to WT and DH69/V70 NTD of 12 NTD-specific mAbs.
(E) Biolayer interferometry analysis of binding to wild-type (WT; black) and WT
association phase from the dissociation phase. Shown is 1 of 2 independent exp
(F) Side-by-side comparison of binding to WT (black) and DH69/V70 (red) NTDs b
S2L28 mAb is not shown because of too little response measured (<0.10 nm).
(G) Binding to NTD of the 11 mAbs shown in (B), expressed as fold change of th
Data are representative of two independent experiments.via the plasma membrane-associated protease TMPRSS2. To
determine the mechanism by which increased spike cleavage
in the context of DH69/V70 might affect entry, we used an inhib-
itor of furin cleavage (CMK) and protease inhibitors specific to
the endosomal (ED64D) and plasma membrane fusion (camo-
stat) entry routes (Figure 4A). We first treated producer cells
with CMK and found that CMK inhibits spike S1/S2 cleavage in
producer cells transfected with the S DH69/V70 plasmid and
that the spikes with altered S1/S2 cleavage are incorporated
into the virions (Figure 4B). We found that CMK treatment,
although reducing S1/S2 cleavage, did not decrease PV infec-
tion in a variety of target cells (Figure 4C), suggesting that the
increased infectivity in DH69/V70 is not due to more efficient
cleavage of spike. To confirm our findings, we generated a spike
lacking the polybasic cleavage site (PBCS) with or withoutDH69/
V70 and tested PV infectivity on HEK293T cells overexpressing
ACE2 and TMPRSS2. We found that deletion of the polybasic
cleavage site led to increased infectivity of the PV, as observed
previously for mutated PBCS (Papa et al., 2021). As expected,
deletion of the PBCS did not alter the enhancing effect of
DH69/V70 on PV infectivity (Figure 4D).
The altered level of S1/S2 cleavage in SARS-CoV-2 has been
linked to its dependence on viral entry through membrane fusion
or endocytosis in HEK293T and A549 cells (Peacock et al., 2020;
Winstone et al., 2021). We therefore hypothesized that the
increased spike cleavage of DH69/V70 S could influence the
route of entry. To probe this, spike pseudotyped lentiviruses
bearing WT spike, DH69/V70 spike, or vesicular stomatitis virus
G protein (VSV-G) were used to transduce HEK293T-ACE2 or
HEK293T-ACE2/TMPRSS2 cells in the presence of E64D or ca-
mostat at different drug concentrations (Figure 4E). As expected,
the VSV-G pseudotyped particles were not affected by addition
of E64D or camostat. Consistent with previous observations, the
WT PV utilized endocytosis in the absence of TMPRSS2 (Pea-
cock et al., 2020), but where TMPRSS2 was expressed, plasma
membrane fusion became the dominant route (Papa et al., 2021;
Winstone et al., 2021). However, there were no differences be-
tween WT and DH69/V70 in relative utilization of the endosomal
versus plasma membrane entry routes. We conclude that the
enhanced spike cleavage, although notable in DH69/V70, does
not appear to be responsible for the increased infectivity of
DH69/V70 spike observed in these cell line-based experiments.
DH69/V70 spike compensates for reduced infectivity of
RBD escape mutants
We next examined in greater detail the SARS-CoV-2 lineages
where S mutations in the RBD were identified at high frequency
and where DH69/V70 co-occurs. For example, N439K, an amino
acid replacement reported to define variants increasing in
numbers in Europe and other regions (Thomson et al., 2020;DH69/V70 (red) NTDs by 12 NTD-targeting mAbs. Dotted lines separate the
eriments.
y 11 NTD-targeting mAbs. Binding is shown as area under the curve (AUC). The
e AUC of the WT compared with DH69/V70.
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Figure 3. Spike DH69/V70 enhances entry and is accompanied by increased spike S2 incorporation into virions
(A) Single-round infectivity on different cell targets by spike DH69/V70 versus the WT PV produced in HEK293T cells. Data are representative of at least three
independent experiments. Data are shown with mean and SEM, and the statistics were performed using unpaired Student’s t test.
(B) Infectivity of DH69/V70 PV on target HeLa cells transduced with ACE2, expressed as fold change relative to the WT. Mean and SEM are shown; one-sample t
test, **p < 0.01
(C–E) Western blots and quantification of virions with infectivity shown in (B) and of cell lysates of HEK293T producer cells following transfection with plasmids
expressing lentiviral vectors and SARS-CoV-2 S DH69/V70 versus the WT (all with D614G), probed with antibodies for HIV-1 p24 and SARS-Cov-2 S2 (C).
(legend continued on next page)






OPEN ACCESSFigures 1 and 5A) now mostly co-occurs with DH69/V70. N439K
appears to have reduced susceptibility to some convalescent
sera as well as mAbs targeting the RBD while increasing affinity
for ACE2 in vitro (Thomson et al., 2021). The first lineage pos-
sessing N439K (and not DH69/V70), B.1.141, is now extinct
(Thomson et al., 2020). A second lineage with N439K, B.1.258,
emerged later and subsequently acquired DH69/V70, leading
to the initial rapid increase in the frequency of viruses possessing
this deletion, spreading into Europe (Figure 1A; Brejová et al.,
2021).
The second significant cluster with DH69/V70 and RBD mu-
tants involves Y453F, another spike RBDmutation that increases
binding affinity to ACE2 (Starr et al., 2020b), and has been found
to be associated with mink-human infection (Munnink et al.,
2021). Y453F has also been described as an escape mutation
for mAb REGN10933, shows reduced susceptibility to convales-
cent sera (Baum et al., 2020; Hoffmann et al., 2021), and is
possibly a T cell escape mutation (Motozono et al., 2021).
DH69/V70 was first detected in the Y453F background on
August 24, 2020 and so far appears to be limited to Danish se-
quences (Figures 1 and 5B), although an independent acquisition
was recently reported along with DH69/V70 in an immune-
compromised Russian individual with chronic infection (Bazykin
et al., 2021).
We hypothesized that DH69/V70 might have arisen after
Y453F and N439K to compensate for potential loss of infectivity,
which has been reported previously for these RBDmutants (Mo-
tozono et al., 2021; Thomson et al., 2021). We therefore gener-
ated mutant spike plasmids bearing RBD mutations Y453F and
N439K (Figure 5C) with and without DH69/V70 and performed
infectivity assays in the lentiviral pseudotyping system. RBDmu-
tations reduced infectivity of spike relative to the WT by around
2-fold (Figure 5D) andwas partially rescued byDH69/V70. Based
on observations of the effect ofDH69/V70 on spike incorporation
in the WT (Figure 3D), we predicted that the mechanism of
increased infectivity for DH69/V70 in the context of RBD muta-
tions might be similar. Analysis of virions from cell supernatants
and cell lysates indeed showed an increased ratio of spike:p24
(Figures 5E and 5F). As observed for the WT, we also observed
increased cleaved S2:FL when DH69/V70 was present along
with the RBD mutants in PVs (Figures 5E and 5G).
DH69/V70 is required for optimal B.1.1.7 Alpha variant
spike S2 incorporation and infectivity
A lineage containing DH69/V70 was first detected in the United
Kingdom with the RBD mutation N501Y along with multiple other
spike and other mutations (Figure 1; Figure S2). Sequences(D) Quantification of spike:p24 ratio in supernatants for WT virus with DH69/V70 v
shown; one-sample t test, ***p < 0.001.
(E). Quantification of cleaved S2 spike: FL spike for WT virus with DH69/V70 vers
experiment.
(F) Infectivity ofDH69/V70 PV produced in H1299 lung epithelial cells on target HEK
was performed using unpaired Student’s t test.
(G) Western blots of virions and cell lysates of H1299 lung epithelial producer cel
CoV-2 S DH69/V70 versus the WT (all with D614G).
(H) Quantification of the S2:FL ratio in purified virions from H1299 lung epithelial
Data from at least two independent experiments are shown. RLU: relative light ubelonging to this lineage were subsequently called B.1.1.7 and
classified as a variant of concern (VOC) due to a higher rate of
transmission (Volz et al., 2021b). It was more recently named
the Alpha variant by WHO. Subsequently B.1.1.7 has spread
rapidly to over 100 countries, exemplifying a new chapter in the
pandemic, with additional VOCs detected in other geographical
locations. In addition to RBD N501Y and NTD DH69/V70,
B.1.1.7 is defined by further S mutations across S2 (T716I,
S982A, and D1118H) and S1 (DY144, A570D, and P681H) (Fig-
ure 6A; Rambaut et al., 2020). The available sequence data did
not enable determination of whether the Alpha variant B.1.1.7mu-
tations N501Y and DH69/V70 arose as a result of an N501Y virus
acquiring DH69/V70 or vice versa, although a United Kingdom
Alpha variant B.1.1.7 sequence was identified with N501Y,
A570D, DH69/V70, and D1118H (Figure S2).
To ascertain whether H69V70 is a target for neutralizing anti-
bodies in the context of the Alpha variant B.1.1.7, we first tested
12NTD-specificmAbs isolated from 4 individuals who recovered
fromWT SARS-CoV-2 infection with an in-vitro PV neutralization
assay using WT SARS-CoV-2 S and the B.1.1.7 S or B.1.1.7 S
with reversion of the H69/V70 deletions (B.1.1.7 H69/V70) PVs
in VeroE6 target cells expressing TMPRSS2. We found that 7
of 12 NTD-specific mAbs (58%) showed a marked decrease or
complete loss of neutralizing activity to B.1.1.7 and B.1.1.7
H69/V70 (>30-fold-change reduction), suggesting that, in a size-
able fraction of NTD antibodies, the H69/V70 deletion is not
responsible for their loss of neutralizing activity (Figure S3). The
remaining 5 mAbs showed a partial reduction (2- to 10-fold) in
Alpha variant B.1.1.7 neutralization that was not rescued by
reversion of the H69/V70 deletions.
Given our data on introduction of DH69/V70 into the WT
(Figure 3), we hypothesized that DH69/V70 was selected in
the evolution of Alpha variant B.1.1.7 to increase viral entry.
We predicted that replacement of H69 and V70 would
impair the infectivity of the B.1.1.7 PV and reduce total spike
levels. To examine this, we compared the infectivity of the
B.1.1.7 spike PV versus the B.1.1.7 PV with restored H69 and
V70. We observed that B.1.1.7 infectivity was slightly lower
than that of the WT (Figure 6B). As expected, we observed a
significant reduction in infectivity for viruses where H69 and
V70 had been re-inserted across a number of cell types,
including H1299 expressing endogenous levels of ACE2 and
TMPRSS2 receptors (Figures 6B and 6C). When we measured
spike incorporation into virions, we found that the reduced
infectivity of B.1.1.7 with replaced H69 V70 was associated
with reduced spike:p24 and S2:FL ratios, as expected (Figures
6D–6G).ersus the WT alone across multiple replicate experiments. Mean and SEM are
us the WT alone in virions and cell lysates. Each data point represents a single
293T cells transiently expressing ACE2 and TMPRSS2. The statistical analysis
ls following transfection with plasmids expressing lentiviral vectors and SARS-
producer cells.
nits; RT: reverse transcriptase.






Figure 4. The route of SARS-CoV-2 S-medi-
ated virus entry in cell lines is not altered by
DH69/V70 spike
(A) Schematic illustrating spike in producer cells
with CMK targeting and blocking furin cleavage
(left panel). In target cells, camostat inhibits
TMPRSS2 and, therefore, cell fusion at the plasma
membrane, and E64D blocks cathepsins and tar-
gets endocytic viral entry (right panel).
(B)Western blots show that CMK inhibits spike S1/
S2 cleavage in producer cells transfected with the
S DH69/V70 plasmid, and spikes with altered S1/
S2 cleavage are incorporated into the virions.
Antibodies against HIV-1 p24 and spike S2 were
used with anti-GAPDH as a loading control.
(C) The viruses produced from transfected
HEK293T cells in the presence of CMK were used
to transduce target cells. The luciferase reading is
used as a surrogate for the spike infectivity bearing
with various S2/FL ratios. The data shown are
technical triplicates or quadruplicates, and statical
analysis was done using an unpaired t test.
(D) Comparison of the infectivity of spike with the
PBCS deleted (DPBCS) with and without DH69/
V70. The effect of DH69/V70 is independent of the
PBCS.
(E)DH69/V70 does not alter the virus entry route. S
pseudotyped lentiviruses bearing WT S, DH69/
V70 S, or VSV-G were used to transduce 293T-
ACE2 or 293T-ACE2/TMPRSS2 cells in the pres-
ence of E64D or camostat at different drug con-
centrations. The cells were then harvested after
2 days and assayed for luciferase expression,
which was then normalized against the non-drug
control (set as 100%). The data shown are tech-
nical duplicates.




OPEN ACCESSAlpha variant B.1.1.7 spike mediates faster syncytium
formation and is DH69/V70 dependent
Previous reports have shown that the SARS-CoV-2 spike pro-
tein localizes to the cell host plasma membrane and pos-
sesses high fusogenic activity, triggering formation of large
multi-nucleated cells (called syncytia) in vitro and in vivo,
potentially providing an additional and a more rapid route for
virus dissemination among neighbor cells (Bussani et al.,
2020; Cattin-Ortolá et al., 2020; Papa et al., 2021). The role
of syncytium formation in viral replication and pathogenesis
of severe coronavirus disease 2019 (COVID-19) has been
reported and may be a druggable process to treat COVID-198 Cell Reports 35, 109292, June 29, 2021pathology (Braga et al., 2021). We ex-
pressed B.1.1.7 spike or a B.1.1.7 with
restored H69 and V70 together with
the mCherry fluorescent protein in
HEK293T cells and labeled Vero cells
with a green fluorescent dye (Figure 7A).
All spike constructs showed similar pro-
tein expression and achieved similar
cell-cell fusion by 16 h. B.1.1.7 ap-
peared to mediate more cell-cell fusionevents over earlier time points, with the color overlap area
being 2–3 times greater for B.1.1.7 compared with the WT
6 h after mixing. Interestingly, this enhancement was abro-
gated by re-insertion of the H69 and V70 residues (Figures
7B–7D). We conclude that B.1.1.7 spike mediates faster fusion
kinetics than the WT bearing D614G Wuhan-1 spike that is
dependent on DH69/V70.
DH69/V70 does not enhance infectivity of bat
coronavirus RaTG13 spike
Finally, to investigate the importance of this part of spike
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OPEN ACCESSpotential, we examined the 69/70 region of spike in a set of
other known sarbecoviruses (Figures S4A–S4C). We observed
substantial variability in the region, resulting in frequent inser-
tions or deletions (indels), with some viruses including SARS-
CoV having 6- to 7-amino-acid deletions (Figure S4B). This is
indicative of high structural plasticity in this protein region that
could allow sarbecoviruses to alter their spike conformation.
RaTG13 is the evolutionarily closest relative to SARS-CoV-2
for this region and, after RaTG13, is the cluster of 5 CoVs
sampled in trafficked pangolins in the Guangxi province
(Lam et al., 2020). Inspection of the 69/70 region in these virus
sequences raises the interesting observation that one of the
five viruses in the cluster, P2V, has amino acids 69H and
70L present, whereas the other four have a double amino
acid deletion (Figures S4A–S4C). Given that SARS-CoV-2
and RaTG13 have the homologous HV insertion at these posi-
tions, one explanation is that the proximal common ancestor
between SARS-CoV-2 and the Guangxi pangolin cluster had
the insertion, which was then lost while circulating in the
pangolin population, similar to observations with SARS-CoV-
2 in humans. However, the fact that P2V was cultured in
Vero E6 cells prior to sequencing (contrary to the other 4,
sequenced directly from the pangolin sample) raises the pos-
sibility of this being an independent insertion, favored as a
monkey cell line-specific adaptation. Interestingly, the double
amino acid indel in the pangolin viruses is in frame, in contrast
to SARS-CoV-2.
Furthermore, the two almost identical bat viruses sequenced
recently from Cambodian samples, RShSTT182 and
RShSTT200 (Hul et al., 2021), possess an H69V70 insertion
despite being more distantly related to SARS-CoV-2 for this re-
gion of spike (Figures S4A–S4C). This independent occurrence
of the insertion is suggestive of context-dependent selective
pressure playing a role in recurring gain and loss of these two
residues in sarbecoviruses. To test whether the fitness effect
associated with acquisition of DH69/V70 is specific to SARS-
CoV-2 and not other sarbecovirus spike backgrounds,
we cloned FL S from RaTG13 and generated pseudotyped len-
tiviruses expressing RaTG13 spike protein as well as a
RaTG13 S DH69/V70 counterpart. We observed that cleaved
and uncleaved S expression levels in the PV did not differ be-
tween WT and the DH69/V70 RaTG13 spike and that there
was no difference in infectivity on target cells expressing ACE2
or ACE2 and TMPRSS2 (Figures S4D and S4E). This result sug-
gests that, as one would expect, the enhancing effect of DH69/
V70 on spike levels and infectivity is specific to the spike
background.Figure 5. DH69/V70 appears after spike N439K and Y453F and compen
(A and B) Maximum-likelihood phylogeny of global sequences carrying Spike mut
S:439K or S:Y453F (February 18, 2021) were downloaded, realigned to Wuhan-H
(C) Representation of the Spike RBM:ACE2 interface (PDB: 6M0J) with residues
(D–F) Spike mutant DH69/V70 compensates for the infectivity defect of spike RB
(D) Infectivity of spike (D614G) DH69/V70 in the absence and presence of spike
tiviruses pseudotyped with SARS-CoV-2 spike protein on target HeLa cells stab
(E) Representative western blot of purified virions and cell lysates probed with an
(F and G) Densitometric quantification of the (F) spike:p24 and (G) cleaved S2 spik
spike RBD mutations across multiple experiments in pelleted viruses. U, unit of r
Data are representative of at least two independent experiments. Student’s t tes
10 Cell Reports 35, 109292, June 29, 2021DISCUSSION
We have presented data demonstrating multiple independent
and circulating lineages of SARS-CoV-2 variants bearing spike
DH69/V70. This recurring deletion, spanning 6 nt, is due to an
out-of-frame deletion of 6 nt and occurs in the terminal loop of
a helix loop motif within the predicted RNA structure, as do other
NTD deletions observed in new variants, such as B.1.1.7 (Alpha),
B.1.617 (Delta), B.1.351 (Beta), and P.1 (Gamma) (Figure S5).
Stable helix loopmotifs are associatedwith pausing/dissociation
events in reverse transcriptase (Harrison et al., 1998). Because
all nucleic acid polymerases have a common ancestor with ho-
mologous dinucleotide triphosphate (dNTP) binding motifs and
similar global structures (Delarue et al., 1990; Ollis et al., 1985;
Sousa et al., 1993), it is probable that all RNA polymerases use
similar mechanisms for transcript termination (Reeder and
Lang, 1994). A recent in-cell biochemical analysis of SARS-
CoV2 RNA structure showed nucleotide reactivity consistent
with this model within these stem-loops (Huston et al., 2021).
These analyses provide a rationale for preferential emergence
of DH69/V70 and other deletions, such as the well-described
NTD antibody escape deletionDY144 (Chi et al., 2020; McCarthy
et al., 2020, 2021) (in B.1.1.7 and the recently reported B.1.525)
at the terminal loops of helical loop motifs. DH69/V70 itself has
frequently followed immune escape-associated amino acid re-
placements in the RBD (e.g., N439K and Y453F) and is specif-
ically found in the B.1.1.7 variant, known to have higher transmis-
sibility (Volz et al., 2021a) and, possibly, pathogenicity (Davies
et al., 2021).
We find thatDH69/V70 does not significantly reduce the sensi-
tivity of spike to neutralizing antibodies in serum from a group of
recovered individuals or binding of multiple mAbs directed
against the NTD. In addition, we have shown that repair of
DH69/V70 does not appreciably alter the potency of NTD anti-
bodies against the B.1.1.7 spike. Thus, the deletion is unlikely
to be an immune escape mechanism. Instead, our experimental
results demonstrate that DH69/V70 is able increase infectivity of
theWuhan-1 D614G spike PV as well as the PV bearing the addi-
tional RBD mutations N439K or Y453F, explaining why the dele-
tion is often observed after these immune escape mutations that
carry infectivity cost (Motozono et al., 2021; Thomson et al.,
2021). We show that the mechanism of enhanced infectivity
across the RBD mutations tested is associated with greater
spike incorporation into virions where DH69/V70 is present.
The phenotype is also independent of producer cells used.
Importantly, we were able to recapitulate the DH69/V70 pheno-
type in a spike protein that did not have the D614G mutation,sates for their reduced infectivity
ant (A) N439K and (B) Y453F. All sequences in the GISAID database containing
u-1 using MAFFT, and deduplicated.
N439, Y453, and N501, highlighted as spheres colored by element.
D mutations and is associated with increased spike incorporation into virions.
RBD mutations. Shown is single-round infection by luciferase-expressing len-
ly transduced with ACE2. Mean and SEM are shown.
tibodies against HIV-1 p24, SARS-CoV-2 spike S2, and GAPDH.
e:FL spike ratios for spike (D614G) DH69/V70 in the absence and presence of
everse transcriptase (RT) activity.







Figure 6. Spike DH69/V70 in B.1.1.7 en-
hances spike infectivity
(A) Surface representation of the spike homotrimer
in open conformation with one upright RBD over-
laid with ribbon representation (PDB: 6ZGG;
Wrobel et al., 2020), with different monomers
shown in black, pale blue, and gold. The deleted
residues H69 and V70 and the residues involved in
amino acid substitutions (501, 570, 716, 982, and
1118) and the deletion at position 144 are colored
red on each monomer and labeled on the mono-
mer with an upright RBD shown in black. Scissors
mark the approximate location of an exposed loop
(residues 677–688) containing the furin cleavage
site and including residue 681, which is absent
from the structure.
(B) Representative infectivity of B.1.1.7 with
replacement of H69 and V70 versus B.1.1.7 con-
taining spike DH69/V70 and WT (D614G) spike;
single-round infection by luciferase-expressing
lentiviruses pseudotyped with SARS-CoV-2 spike
protein on HeLa cells transduced with ACE2. The
data represent technical triplicates.
(C) Fold change of luciferase expression over the
replacement of H69V70 in ACE2-transfected and
ACE2- and TMPRSS2-transfected HEK293T cells,
A459-ACE2/TMPRSS2 cells, and H1299 cells. The
data shown are from three independent experi-
ments, each in technical triplicates (one-sample
t test).
(D) Representative western blot analysis following
transfection of HEK293T cells with spike and len-
tiviral plasmids. Virion loading was normalized for
input virus using RT activity. Antibodies against
HIV-1 p24 and spike S2 were used with anti-
GAPDH as a loading control.
(E and F) S2 to FL spike was analyzed by densi-
tometry, and the S2:FL cleavage ratio was calcu-
lated for virions (E) and cell lysates (F).
(G) Quantification of the spike:p24 ratio for B.1.1.7
and B.1.1.7 with H69/V70 replacement across
three independent experiments.
**p < 0.01, ****p < 0.0001.
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OPEN ACCESSindicating that D614G is not involved in the mechanism. These
observations are supported by DH69/V70 being observed in
D614 viruses in January 2020 in the United States and Thailand.
Although we did not use a replication-competent system, a
recent study reports that the DH69/V70 mutated Washingtonstrain virus isolate confers increased
replication in cell lines and higher viral
loads in hamsters (Liu et al., 2021).
Indeed, DH69 has been observed in cell
culture during remdesivir selection exper-
iments with a replication-competent vi-
rus, consistent with a replication advan-
tage (Szemiel et al., 2021).
We have found consistent differences
in spike as well as cleaved spike in the
producer cell and its incorporation into
PV particles when comparing DH69/
V70 with a Wuhan-1 spike (both withD614G). This could be explained by stability during intracel-
lular trafficking or the route taken to the surface, differences
in post-translational modification of the spike protein, or mem-
brane characteristics at the budding site of virus or virus-like




Figure 7. DH69/V70 significantly acceler-
ates cell-cell fusion activity of Alpha variant
B.1.1.7 spike protein
(A) Schematic of the cell-cell fusion assay (created
with BioRender).
(B) Reconstructed images at 6 h of HEK293T cells
co-transfected with the indicated spike mutants
and mCherry-expressing plasmid mixed with
green dye-labeled Vero acceptor cells. Scale bars
represent 100mm. Green identifies acceptor cells,
and red marks donor cells. Merged green-red in-
dicates syncytia.
(C) Quantification of cell-cell fusion kinetics,
showing percentage of green and red overlap area
over time. Mean is plotted, with error bars repre-
senting SEM.
(D) Quantification of cell-cell fusion of the indi-
cated spike mutants 6 h after transfection. Mean is
plotted, with error bars representing SEM.
(E) Representative western blot of cells trans-
fected with the indicated spike mutants (detected
with anti-S2 antibody). The S2 subunit is indicated
by an arrowhead. b-Actin is shown as a loading
control.
Data are representative of at least three indepen-
dent experiments. *p < 0.05, unpaired t test.
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OPEN ACCESSvirions reflects the spike in the cells, virion formation is likely
unaffected by DH69/V70. Interestingly, although pharmaco-
logical inhibition of furin by CMK in producer cells did prevent
S1/S2 cleavage and altered the balance of S2:FL spike in cells
and virions, PV infectivity was not reduced by drug treatment.
These data suggest that the increase in entry efficiency
conferred by spike DH69/V70 is independent of spike S1/S2
cleavage. Similar findings regarding the lack of relationship
between the balance of S2:FL and infectivity have been re-
ported in the context of furin knockout cells rather than furin
inhibition with CMK (Papa et al., 2021). In addition, a recent
report on the S1/S2 cleavage site mutation P681H demon-
strated that enhanced cleavage of spike P681H was not asso-
ciated with increased PV infectivity or cell fusion relative to the
WT (Lubinski et al., 2021). There may, however, be differences
in vivo.
We explored the entry route of DH69/V70 spike using
cathepsin inhibition to block endosomal entry and camostat to
block entry via plasma membrane fusion. DH69/V70 spike was
as sensitive to camostat and the cathepsin inhibitor ED64 as
theWT, arguing that the efficiency of entry route is similar despite
differences in cleaved spike. Although S1/S2 cleavage
allows avoidance of endosome-associated IFITM restriction12 Cell Reports 35, 109292, June 29, 2021and appears to be critical for transmis-
sion in animal models (Peacock et al.,
2020), cleaved spike may be less infec-
tious when S1 is shed prematurely,
possibly conferring a disadvantage under
some circumstances. In addition, Pea-
cock et al. (2020) showed that S1/S2
cleavage in the producer cell, conferred
by a polybasic stretch at the cleavagesite, is advantageous in cells expressing abundant TMPRSS2
but deleterious in cells lacking TMPRSS2.
The Alpha variant Al (B.1.1.7), bearing seven spike mutations,
is responsible for a new pandemic phase that is demonstrably
more pathogenic (Davies et al., 2021) and more transmissible
(Volz et al., 2021a). Detection of a high number of novel muta-
tions suggests that this lineage has been introduced from a
geographic region with very poor sampling or that viral evolution
may have occurred in a single individual in the context of chronic
infection (Kemp et al., 2021).
We show that Alpha variant B.1.1.7 spike has similar infec-
tivity as WT D614G spike, consistent with data on live B.1.1.7
virus in human airway epithelial cells (Brown et al., 2021) but in
contrast to another study that showed a difference in live
virus with the 8 spike mutations (Liu et al., 2021). Importantly,
however, we demonstrate loss of infectivity when the H69/
V70 amino acids are replaced in B.1.1.7 S, accompanied,
as expected, by reduced S1/S2 cleavage and reduced S
incorporation into virions. These data point to epistatic inter-
actions between observed mutations in spike of B.1.1.7 with
a trade-off between mutations that incur virus entry cost




OPEN ACCESSOf greatest potential importance is our observation that Alpha
variant B.1.1.7 spike mediates faster syncytium formation and
that this enhanced cell-cell fusion activity is dependent on
DH69/V70. Syncytium formation is a key feature of severe and
fatal COVID-19 (Bussani et al., 2020) and implicated in elevated
viral replication (Braga et al., 2021). We speculate that the
increased fusogenicity of B.1.1.7 spike may contribute to the
higher mortality (Davies et al., 2021) and transmissibility of
B.1.1.7 (Volz et al., 2021a).
Limitations
Although we combined epidemiological, evolutionary, protein
and RNA structure, and experimental data in our study, a lim-
itation is that the experiments were conducted with PVs and
coronavirus-like particles rather than replication-competent
viruses. We also carried out experiments in cells overexpress-
ing receptors, although the results were recapitulated in
lung cell lines expressing endogenous levels of ACE2 and
TMPRSS2.
Detection and surveillance of B.1.1.7 has been facilitated in
the United Kingdom by the phenomenon of SGTF (S[pike] gene
target failure) because of primers in the Thermo Fisher Scientific
SARS-CoV-2 diagnostic qPCR assay used by a significant num-
ber of testing facilities. The S gene target (binding in the region of
H69/V70) is one of three; therefore, a marker for the spread of
B.1.1.7 has been tracked by loss of signal in the S gene target
(Volz et al., 2021b). However, recent reports from the United
States and central Europe caution against use of SGTF as a
sole marker for B.1.1.7 detection because a significant DH69/
V70 lineage without other mutations in spike is circulating in
the United States, and a B.1.258 lineage with N439K with
DH69/V70 is circulating in Slovakia/Czech Republic (Brejová
et al., 2021; Larsen and Worobey, 2020). Such examples high-
light the need for genome sequencing to accompany novel ap-
proaches to diagnostics for variants.
Given the emergence of multiple clusters of variants car-
rying RBD mutations and DH69/V70 , limitation of transmis-
sion takes on renewed urgency. As another example, a new
VOC bearing DH69/V70 with E484K was recently identified
(B.1.525). Comprehensive vaccination efforts should be accel-
erated to limit transmission and acquisition of further muta-
tions, and future vaccines could include DH69/V70 to close
this route for virus evolution, assuming that effective neutral-
izing antibodies to this region are generated. Fortunately,
our experiments with RaTG13 demonstrate that DH69/V70
may not enhance the infectivity of other bat sarbecoviruses
with zoonotic potential.
We found that a two-amino-acid deletion, DH69/V70, pro-
motes SARS-CoV-2 spike incorporation into viral particles and
increases infectivity by a mechanism that remains to be fully ex-
plained. This deletion has arisen multiple times and often after
spike antibody escape mutations that reduce spike-mediated
entry efficiency. Critically, B.1.1.7 spike mediates faster synci-
tium formation, and this enhanced cell-cell fusion activity is
dependent on DH69/V70. In addition, B.1.1.7 spike requires
DH69/V70 for optimal infectivity, and we conclude that DH69/
V70 enables SARS-CoV-2 to tolerate multiple immune escape
mutations while maintaining infectivity and fusogenicity.STAR+METHODS
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Materials availability
This study did not generate new unique reagents.
Data and code availability
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
The study was primarily a laboratory based study using pseudotyped virus (PV) with mutations generates by site directed mutagen-
esis.We tested infectivity in cell lines with a range of drug inhibitors andmonoclonal antibodies. Sensitivity to antibodies in serumwas
tested using convalescent sera from recovered individuals collected as part of the Cambridge NIHR Bioresource. We also performed
phylogenetic analyses of data available publicly in GISAID.
Ethical approval
Ethical approval for use of serum samples. Controls with COVID-19 were enrolled to the NIHR BioResource Centre Cambridge under
ethics review board (17/EE/0025).
METHOD DETAILS
Phylogenetic analysis
All available full-genome SARS-CoV-2 sequenceswere downloaded from the GISAID database (https://gisaid.org/; Shu andMcCau-
ley, 2017) on 16th February 2021. Low-quality sequences (> 5% N regions) were removed, leaving a dataset of 491,395 sequences
with a length of > 29,000bp. Sequences were deduplicated and then filtered to find the mutations of interest. All sequences were
realigned to the SARS-CoV-2 reference strain MN908947.3, using MAFFT v7.475 with automatic strategy selection and the–keep-
length–addfragments options (Katoh and Standley, 2013). Major SARS-CoV-2 clade memberships were assigned to all sequences
using the Nextclade server v0.13 (https://clades.nextstrain.org/), Pangolin v2.4.2 (Rambaut et al., 2020a); https://github.com/
cov-lineages/pangolin) and a local instance of the PangoLEARN model, dated 18th April 21:49 (https://github.com/cov-lineages/
pangoLEARN).
Maximum likelihood phylogenetic trees were produced using the above curated dataset using IQ-TREE v2.1.2 (Minh et al., 2020).
Evolutionary model selection for trees were inferred using ModelFinder (Kalyaanamoorthy et al., 2017) and trees were estimatedCell Reports 35, 109292, June 29, 2021 e2
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OPEN ACCESSusing the GTR+F+I model with 1000 ultrafast bootstrap replicates (Minh et al., 2013). All trees were visualized with Figtree v.1.4.4
(http://tree.bio.ed.ac.uk/software/figtree/) and ggtree v2.2.4 rooted on the SARS-CoV-2 reference sequence and nodes arranged
in descending order. Nodes with bootstraps values of < 50 were collapsed using an in-house script.
To reconstruct a phylogeny for the 69/70 spike region of the 20 Sarbecoviruses examined in Figure S4, Rdp5 (Martin et al., 2015)
was used on the codon spike alignment to determine the region between amino acids 1 and 256 as putatively non-recombinant. A
tree was reconstructed using the nucleotide alignment of this region under a GTR+G substitution model with RAxML-NG (Kozlov
et al., 2019). Node support was calculated with 1000 bootstraps. Alignment visualization was done using BioEdit (Hall et al., 2011).
Structural modeling
The structure of the post-deletion NTD (residues 14-306) was modeled using I-TASSER (Roy et al., 2010), a method involving detec-
tion of templates from the protein data bank, fragment structure assembly using replica-exchange Monte Carlo simulation and
atomic-level refinement of structure using a fragment-guided molecular dynamics simulation. The structural model generated was
aligned with the spike structure possessing the pre-deletion conformation of the 69-77 loop (PDB 7C2L (Chi et al., 2020)) using Py-
MOL (Schrödinger). Figures prepared with PyMOL using PDBs 7C2L, 6M0J (Lan et al., 2020), 6ZGE28 and 6ZGG (Wrobel et al.,
2020).
RNA secondary structure modeling
2990 nucleotides centered around the spike protein amino acids 69-70 from SARS-CoV2 sequence from an individual12 were aligned
in CLUSATL-Omega (nucleotides 20277-23265 of the Wuhan isolate MN908947.3) and a consensus structure was generated using
RNAalifold (Bernhart et al., 2008)).
Cells
HEK293T CRL-3216, Vero CCL-81 were purchased from ATCC and maintained in Dulbecco’s Modified Eagle Medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100mg/ml streptomycin. All cells are regularly tested and are
mycoplasma free. H1299 cells were a kind gift from Simon Cook. Calu-3 cells were a kind gift from Paul Lehner, A549 A2T2 (Rihn
et al., 2021) cells were a kind gift from Massimo Palmerini.
Pseudotype virus preparation
Plasmids encoding the spike protein of SARS-CoV-2 D614 with a C-terminal 19 amino acid deletion with D614G, were used as a
template to produce variants lacking amino acids at position H69 and V70, as well as mutations N439K and Y453F. Mutations
were introduced using Quickchange Lightning Site-Directed Mutagenesis kit (Agilent) following the manufacturer’s instructions.
B.1.1.7 S expressing plasmid preparation was described previously by step wise mutagenesis (Collier et al., 2021). Viral vectors
were prepared by transfection of 293T cells by using Fugene HD transfection reagent (Promega). 293T cells were transfected
with a mixture of 11ul of Fugene HD, 1mg of pCDNAD19 spike-HA, 1ug of p8.91 HIV-1 gag-pol expression vector and 1.5mg of
pCSFLW (expressing the firefly luciferase reporter gene with the HIV-1 packaging signal). Viral supernatant was collected at 48
and 72h after transfection, filtered through 0.45um filter and stored at 80C as previously described. Infectivity was measured
by luciferase detection in target 293T cells transfected with TMPRSS2 and ACE2.
SARS-CoV-2 D614 (Wuhan) and RaTG13 mutant plasmids and infectivity
Plasmids encoding the full-length spike protein of SARS-CoV-2 D614 (Wuhan) and RaTG13, in frame with a C – terminal Flag tag
(Conceicao et al., 2020), were used as a template to produce variants lacking amino acids at position H69 and V70. The deletion
was introduced using Quickchange Lightning Site-Directed Mutagenesis kit (Agilent) following the manufacturer’s instructions. Vi-
ruses were purified by ultracentrifugation; 25mL of crude preparation being purified on a 20% sucrose cushion at 2300rpm for
2 hr at 4C. After centrifugation, the supernatant was discarded and the viral pellet resuspended in 600 mL DMEM (10% FBS) and
stored at 80C. Infectivity was examined in HEK293 cells transfected with human ACE2, with RLUs normalized to RT activity pre-
sent in the pseudotyped virus preparation by PERT assay.Western blots were performed on purified virus with anti-HIV1 p24, 1:1,000
(Abcam) or anti-FLAG, 1:2,000 (Sigma) antibodies used following SDS-PAGE and transfer.
Standardization of virus input by SYBR green-based product-enhanced PCR assay (SG-PERT)
The reverse transcriptase activity of virus preparations was determined by qPCR using a SYBR Green-based product-enhanced
PCR assay (SG-PERT) as previously described (Vermeire et al., 2012). Briefly, 10-fold dilutions of virus supernatant were lysed in
a 1:1 ratio in a 2x lysis solution (made up of 40% glycerol v/v 0.25% Trition X-100 v/v 100mM KCl, RNase inhibitor 0.8 U/ml, TrisHCL
100mM, buffered to pH7.4) for 10 minutes at room temperature.
12ml of each sample lysate was added to 13ml of a SYBR Green master mix (containing 0.5mM of MS2-RNA Fwd and Rev primers,
3.5pmol/ml of MS2-RNA, and 0.125U/ml of Ribolock RNase inhibitor and cycled in a QuantStudio. Relative amounts of reverse tran-
scriptase activity were determined as the rate of transcription of bacteriophage MS2 RNA, with absolute RT activity calculated by
comparing the relative amounts of RT to an RT standard of known activity.e3 Cell Reports 35, 109292, June 29, 2021
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Plasmids encoding codon-optimized (M)embrane, (E)nvelope and (N)ucleocapsid proteins of SARS-CoV-2 were a kind gift from Ne-
van Krogan (M, pLVX-EF1alpha-SARS-CoV-2-M-2xStrep-IRES-Puro, Addgene #141386; E, pLVX-EF1alpha-SARS-CoV-2-E-
2xStrep-IRES-Puro, Addgene #141385; N, pLVX-EF1alpha-SARS-CoV-2-N-2xStrep-IRES-Puro, Addgene #141391) (Gordon
et al., 2020). For expression in 293T cells, M, E and N were each subcloned into a modified pmaxGFP (Lonza) vector as M/E/N-
IRES-GFP. Plasmids encoding the (S)pike protein of SARS-CoV-2 with a C-terminal 19 amino acid deletion plus/minus the DH69/
V70 deletion are described above (pseudotype virus preparation).
Coronavirus-like particles were prepared essentially as previously described (Swann et al., 2020; Yurkovetskiy et al., 2020). In brief,
43106 293T cells in 10 cm dishes were transfected using TransIT-LT1 (Mirus) with a total of 4 mg DNA comprising 1 mg each of plas-
mids encoding S (WT or DH69/V70), M, E and N. Media was replaced after 16 h.
Supernatants containing coronavirus-like particles were harvested after 2 d, spun for 10 min at 2,000 g, then passed through a
0.45 mm filter. For each condition, 9 mL supernatant was layered on a 2 mL cushion of 20% sucrose in PBS and spun for 2 h at
100,000 g in a Type 70 Ti Beckman Coulter Ultracentrifuge Rotor. The pellet was washed once with PBS, then resuspended in
100 ml 2% SDS in PBS. After aspiration of supernatant, cells were washed twice in PBS, then lysed in 800 ml of 2% SDS in TBS
with 500 units of Benzonase (Sigma-Aldrich). Lysates were incubated for 30 m at room temperature, then spun for 10 min at
13,000 g.
Resuspended pellets containing concentrated coronavirus-like particles were heated in Laemmli buffer with DTT at 95C for 5 min.
For each condition, 30 mL was loaded on a 4%–20%Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad). Cell lysates were quantified
using the Pierce BCA Protein Assay Kit (Thermo Scientific), then heated in Laemmli buffer with DTT at 95C for 5 min. For each con-
dition, 20 mg protein was loaded on an identical gel. Proteins were transferred to 45 nm PDVFmembranes and blocked with 5%milk
in PBS-Tween 0.2%. The following antibodies were used for immunoblotting: anti-S (Invitrogen, PA1-41165); anti-N (Novus Biolog-
icals, NB100-56683) and anti-b-actin (Sigma, A5316).
Spike cleavage inhibition experiments
CMK furin inhibitor experiments: 293T cells were transfected with plasmids expressing Gag/pol, luciferase, and spike. Furin inhibitor
CMK (Calbiochem) was added at either 5 M or 25 mM concentration three hours post transfection. The supernatants and cell lysates
were collected after 48 hours for infectivity on target cells or for western blotting.
E64D and camostat experiments: ACE2 or ACE2 and TMPRSS2 transfected 293T cells were either E64D (Tocris) or camostat
(Sigma-Aldrich) treated for 3 hours at each drug concentration before the addition of a comparable amount of input viruses pseudo-
typed with WT, H69/V70 deletion or VSV-G (approx. 1 million RLU). The cells were then left for 48 hours before addition of substrate
for luciferase (Promega) and read on a Glomax plate reader (Promega). The RLU was normalized against the no-drug control which
was set as 100%.
Cell-cell fusion assay
Cell fusion assay was carried out as previously described (Papa et al., 2021). Briefly, Vero cells and 293T cells were seeded at 80%
confluency in a 24 multiwell plate. 293T cells were co-transfected with 1.5 mg of spike expression plasmids in pCDNA3 and 0.5 mg
mCherry-N1 using Fugene 6 and following themanufacturer’s instructions (Promega). Vero cells were treated with CellTracker Green
CMFDA (5-chloromethylfluorescein diacetate) (Thermo Scientific) for 20 minutes. 293T cells were then detached 5 hours post trans-
fection, mixed together with the green-labeled Vero cells, and plated in a 12 multiwell plate. Cell-cell fusion was measured using an
Incucyte and determined as the proportion of merged area to green area over time. Data were then analyzed using Incucyte software
analysis. Data were normalized to cells transfected only with mCherry protein and mixed with green labeled Vero cells. Graphs were
generated using Prism 8 software.
Western blotting
Cells were lysed and supernatants collected 18 hours post transfection. Purified virions were prepared by harvesting supernatants
and passing through a 0.45 mm filter. Clarified supernatants were then loaded onto a thin layer of 8.4% optiprep density gradient me-
dium (Sigma-Aldrich) and placed in a TLA55 rotor (Beckman Coulter) for ultracentrifugation for 2 hours at 20,000 rpm. The pellet was
then resuspended for western blotting. Cells were lysedwith cell lysis buffer (Cell signaling) or were treated with Benzonase Nuclease
(Millipore) and boiled for 5 min. Samples were then run on 4%–12% Bis Tris gels and transferred onto nitrocellulose or PVDF mem-
branes using an iBlot or semidry (Thermofisher and Biorad, respectively).
Membranes were blocked for 1 hour in 5% non-fat milk in PBS + 0.1% Tween-20 (PBST) at room temperature with agitation, incu-
bated in primary antibody (anti-SARS-CoV-2 Spike, Thermofisher, PA1-41165), anti-GAPDH (proteintech) or anti-p24 (NIBSC))
diluted in 5% non-fat milk in PBST for 2 hours at 4C with agitation, washed four times in PBST for 5 minutes at room temperature
with agitation and incubated in secondary antibody (anti-rabbit or anti-mouseHRP conjugate), anti-bactin HRP (Santa Cruz) diluted in
5% non-fat milk in PBST for 1 hour with agitation at room temperature. Membranes were washed four times in PBST for 5 minutes at
room temperature and imaged directly using a ChemiDoc MP imaging system (Bio-Rad).Cell Reports 35, 109292, June 29, 2021 e4
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Spike pseudotype assays have been shown to have similar characteristics as neutralization testing using fully infectious wild-type
SARS-CoV-2 (Schmidt et al., 2020).Virus neutralization assays were performed on 293T cell transiently transfected with ACE2
and TMPRSS2 using SARS-CoV-2 spike pseudotyped virus expressing luciferase (Mlcochova et al., 2020). Pseudotyped virus
was incubated with serial dilution of heat inactivated human serum samples or convalescent plasma in duplicate for 1h at 37C. Virus
and cell only controls were also included. Then, freshly trypsinized 293T ACE2/TMPRSS2 expressing cells were added to each well.
Following 48h incubation in a 5% CO2 environment at 37
C, the luminescence was measured using Steady-Glo Luciferase assay
system (Promega).
Monoclonal antibody neutralization of B.1.1.7 or B.1.1.7 H69/V70 pseudotyped viruses
Preparation of B.1.1.7 or B.1.1.7 H69/V70 SARS-CoV-2 S glycoprotein-encoding-plasmid used to produce SARS-CoV-2-MLV based
on overlap extension PCR. Briefly, a modification of the overlap extension PCR protocol (Forloni et al., 2018) was used to introduce
the 9 or 7 mutations of the B.1.1.7 and B.1.1.7 H69/V70 lineages, respectively. In a first step, 9 DNA fragments with overlap se-
quences were amplified by PCR from a plasmid (phCMV1, Genlantis) encoding the full-length SARS-CoV-2 S gene (BetaCoV/Wu-
han-Hu-1/2019, accession number mn908947). The mutations (D69/70, D144, N501Y, A570D, D614G, P681H, S982A, T716I and
D1118H or K417N, E484K and N501Y) were introduced by amplification with primers with similar Tm. Deletion of the C-terminal
21 amino acids was introduced to increase surface expression of the recombinant S (Case et al., 2020). Next, 3 contiguous overlap-
ping fragments were fused by a first overlap PCR (step 2) using the utmost external primers of each set, resulting in 3 larger fragments
with overlapping sequences. A final overlap PCR (step 3) was performed on the 3 large fragments using the utmost external primers to
amplify the full-length S gene and the flanking sequences including the restriction sites KpnI and NotI. This fragment was digested
and cloned into the expression plasmid phCMV1. For all PCR reactions theQ5Hot Start High fidelity DNA polymerase was used (New
England Biolabs Inc.), according to themanufacturer’s instructions and adapting the elongation time to the size of the amplicon. After
each PCR step the amplified regions were separated on agarose gel and purified using Illustra GFX PCR DNA and Gel Band Purifi-
cation Kit (Merck KGaA).
Ab discovery and recombinant expression
Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV or SARS-CoV-2 immune donors. Recombinant an-
tibodies were expressed in ExpiCHO cells at 37C and 8%CO2. Cells were transfected using ExpiFectamine. Transfected cells were
supplemented 1 day after transfection with ExpiCHO Feed and ExpiFectamine CHO Enhancer. Cell culture supernatant was
collected eight days after transfection and filtered through a 0.2 mm filter. Recombinant antibodies were affinity purified on an
ÄKTA xpress FPLC device using 5 mL HiTrap MabSelect PrismA columns followed by buffer exchange to Histidine buffer (20 mM
Histidine, 8% sucrose, pH 6) using HiPrep 26/10 desalting columns.
Pseudovirus neutralization assay for testing NTD monoclonal antibodies
MLV-based SARS-CoV-2 S-glycoprotein-pseudotyped viruses were prepared as previously described (Pinto, 2020). HEK293T/
17cells were cotransfected with a WT, B.1.1.7 or B.1.1.7 H69/V70 SARS-CoV-2 spike glycoprotein-encoding-plasmid, an MLV
Gag-Pol packaging construct and the MLV transfer vector encoding a luciferase reporter using X-tremeGENE HP transfection re-
agent (Roche) according to the manufacturer’s instructions. Cells were cultured for 72 h at 37C with 5% CO2 before harvesting
the supernatant. VeroE6 stably expressing human TMPRSS2 were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) con-
taining 10% fetal bovine serum (FBS), 1% penicillin–streptomycin (100 I.U. penicillin/mL, 100 mg/mL), 8 mg/mL puromycin and
plated into 96-well plates for 16–24 h. Pseudovirus with serial dilution of mAbs was incubated for 1 h at 37C and then added
to the wells after washing 2 times with DMEM. After 2–3 h DMEM containing 20% FBS and 2% penicillin–streptomycin was added
to the cells. Following 48-72 h of infection, Bio-Glo (Promega) was added to the cells and incubated in the dark for 15 min before
reading luminescence with Synergy H1 microplate reader (BioTek). Measurements were done in duplicate and relative luciferase
units were converted to percent neutralization and plotted with a non-linear regression model to determine IC50 values using
GraphPad PRISM software (version 9.0.0).
Neutralization assays
Measurements were done in duplicate and relative luciferase units were converted to percent neutralization against no-drug con-
trol which was set as 100%. Data were plotted with a non-linear regression model to determine IC50 values using GraphPad
PRISM software (version 9.0.0). The 50% inhibitory dilution (EC50) was defined as the serum dilution at which the relative light units
(RLUs) were reduced by 50% compared with the virus control wells (virus + cells) after subtraction of the background RLUs in the
control groups with cells only. The EC50 values were calculated with non-linear regression, log (inhibitor) versus normalized
response using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA, USA). The neutralization assay was positive if the
serum achieved at least 50% inhibition at 1 in 3 dilution of the SARS-CoV-2 spike protein pseudotyped virus in the neutralization
assay. The neutralization result was negative if it failed to achieve 50% inhibition at 1 in 3 dilution. Statistical tests are described in
the figure legends along with the value of n, mean, and standard deviation/error. Data were normally distributed consistent with
statistical methods used.e5 Cell Reports 35, 109292, June 29, 2021
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Measurements were done in duplicate and relative luciferase units measured with a Glomax luminometer. Data were analyzed using
GraphPad PRISM software (version 9.0.0). Statistical tests are described in the figure legends along n,mean, and standard deviation/
error. Data were normally distributed consistent with statistical methods used.Cell Reports 35, 109292, June 29, 2021 e6
